» Articles » PMID: 37509330

Opportunities and Alternatives of Modern Radiation Oncology and Surgery for the Management of Resectable Brain Metastases

Abstract

Postsurgical radiotherapy (RT) has been early proven to prevent local tumor recurrence, initially performed with whole brain RT (WBRT). Subsequent to disadvantageous cognitive sequalae for the patient and the broad distribution of modern linear accelerators, focal irradiation of the tumor has omitted WBRT in most cases. In many studies, the effectiveness of local RT of the resection cavity, either as single-fraction stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic RT (hFSRT), has been demonstrated to be effective and safe. However, whereas prospective high-level incidence is still lacking on which dose and fractionation scheme is the best choice for the patient, further ablative techniques have come into play. Neoadjuvant SRS (N-SRS) prior to resection combines straightforward target delineation with an accelerated post-surgical phase, allowing an earlier start of systemic treatment or rehabilitation as indicated. In addition, low-energy intraoperative RT (IORT) on the surgical bed has been introduced as another alternative to external beam RT, offering sterilization of the cavity surface with steep dose gradients towards the healthy brain. This consensus paper summarizes current local treatment strategies for resectable brain metastases regarding available data and patient-centered decision-making.

Citing Articles

Intraoperative glioblastoma surgery-current challenges and clinical trials: An update.

Patel V, Chavda V Cancer Pathog Ther. 2024; 2(4):256-267.

PMID: 39371095 PMC: 11447313. DOI: 10.1016/j.cpt.2023.11.006.


Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment- update of the oncological outcome form a single center cohort after 117 procedures.

Kahl K, Krauss P, Neu M, Maurer C, Schill-Reiner S, Roushan Z J Neurooncol. 2024; 169(1):187-193.

PMID: 38963657 PMC: 11269407. DOI: 10.1007/s11060-024-04691-6.


Cytoreduction of Residual Tumor Burden Is Decisive for Prolonged Survival in Patients with Recurrent Brain Metastases-Retrospective Analysis of 219 Patients.

Lin J, Kaiser Y, Wiestler B, Bernhardt D, Combs S, Delbridge C Cancers (Basel). 2023; 15(20).

PMID: 37894435 PMC: 10605169. DOI: 10.3390/cancers15205067.

References
1.
Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

2.
Bilger A, Bretzinger E, Fennell J, Nieder C, Lorenz H, Oehlke O . Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Cancer Med. 2018; 7(6):2350-2359. PMC: 6010898. DOI: 10.1002/cam4.1486. View

3.
Kowalchuk R, Niranjan A, Lee C, Yang H, Liscak R, Guseynova K . Reirradiation With Stereotactic Radiosurgery After Local or Marginal Recurrence of Brain Metastases From Previous Radiosurgery. Int J Radiat Oncol Biol Phys. 2021; 112(3):726-734. DOI: 10.1016/j.ijrobp.2021.10.008. View

4.
Nguyen M, Noel G, Antoni D . [Reirradiation of brain metastasis: Review of the last five years]. Cancer Radiother. 2019; 23(6-7):531-540. DOI: 10.1016/j.canrad.2019.07.144. View

5.
Boire A, Brastianos P, Garzia L, Valiente M . Brain metastasis. Nat Rev Cancer. 2019; 20(1):4-11. DOI: 10.1038/s41568-019-0220-y. View